Treatment mechanism of erianin for glucocorticoid-induced osteonecrosis of femoral head:network pharmacology and experimental validation
Objective To investigate the potential mechanism of Erianin in the treatment of femoral head necrosis using network pharmacology and experimental approaches.Methods The target genes associated with glucocorticoid-induced osteonecrosis of the femoral head were collected using databases such as GEO.The target genes of Erianin were searched in databases such as Pubchem and HERB.Venn diagrams were used to identify the shared genes,followed by enrich-ment analysis.The optimal drug concentration was determined through cell viability assays,and the effect of different treatment groups on the formation of HUVECs cell tube numbers was assessed using tube formation assay.Results The union of disease target genes and drug target genes yielded 50 intersecting target genes.Enrichment analysis uncovered that the key genes participating in the interaction were primarily linked to the regulation of biological processes,inclu-ding the production of vascular endothelial growth factor and the formation of the endothelial barrier.Experimental results demonstrated that Erianin had no toxic effect on HUVECs cells and led to a higher number of formed blood vessels.Conclusion Erianin,by facilitating angiogenesis,could be considered a prospective therapeutic agent for the clinical management of glucocorticoid-induced osteonecrosis of the femoral head.
ErianinGlucocorticoid-induced osteonecrosis of the femoral headNetwork PharmacologyAngiogencsis
NETL
NSTL
万方数据
